senolytic peptide foxo4-dri human study alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOXO4 DRI Peptide for Cellular Senescence and Anti Aging Research
Pay in 4 interest-free payments of $7.06 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



